PHILADELPHIA Piera Pasinelli, Ph.D., co-director of the Frances and Joseph Weinberg Unit for ALS Research at the Farber Institute for Neurosciences at Thomas Jefferson University was recently awarded a Margaret Q. Landenberger Research Foundation grant to identify why drug therapies that showed promise in Amyotrophic Lateral Sclerosis (ALS) mouse models have proven unsuccessful in human clinical trials. Dr. Pasinelli and her research team will closely examine critical aspects of drug delivery in the central nervous system at the metabolic level with the hope of advancing drug development for ALS. The grant totals $300,000 and will be issued in $100,000 disbursements over three years.
"In spite of recent progress toward understanding the origination of ALS, finding an effective treatment has remained elusive. Our hypothesis is that one reason there is no viable drug therapy for ALS may be that in designing both mouse and human clinical trials, scientists have overlooked critical aspects of drug bioavailability and metabolism." said Dr. Pasinelli. "Proteins called multi-drug resistance transporters are increased during the disease, rendering pharmacological treatments for ALS mostly ineffective. This grant will support research towards finding ways to inactivate these transporter proteins to counteract their negative effect on ALS therapy. We are extremely grateful to the Margaret Q. Landenberger Research Foundation for seeing the potential our work has and awarding us this grant money."
The Margaret Q. Landenberger Research Foundation, which was formed in 1992, is based in Philadelphia, Pennsylvania. Brown Brothers Harriman Trust Company, N.A., serves as the foundation's corporate trustee.
"The Landenberger Foundation provides initial funding for novel medical research projects in the hope that this will help the scientists further expand their research through additional grants from other sources," said William R. Levy, Exe
|Contact: Ed Federico|
Thomas Jefferson University